- Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID‐19Havva, Kocayiğit; Kezban, Özmen Süner; Yakup, Tomak; Gürkan, Demir; Selçuk, Yaylacı; Hamad, Dheir; Ertuğrul, Güçlü; Ali Fuat, ErdemJournal of Clinical Pharmacy and Therapeutics, 2021, 46(2): 454-459.
- Tocilizumab use in patients with moderate to severe COVID‐19: A retrospective cohort studySridhar, Chilimuri; Haozhe, Sun; Ahmed, Alemam; Kyoung‐Sil, Kang; Peter, Lao; Nikhitha, Mantri; Lawrence, Schiller; Myroslava, Sharabun; Elona, Shehi; Jairo, Tejada; Alla, Yugay; Suresh Kumar, NayuduJournal of Clinical Pharmacy and Therapeutics, 2021, 46(2): 440-446.被引 1
- USE OF REPURPOSED AND ADJUVANT DRUGS IN HOSPITAL PATIENTS WITH COVID-19: MULTINATIONAL NETWORK COHORT STUDY (vol 373, n1038, 2021)Zhu, Hong*; Lui, LiBRITISH MEDICAL JOURNAL, 2021, 373: n1277.
期刊论文
No Evidence Indicates Famotidine Reduces the Risk of Serious Disease in COVID-19 Patients After Propensity Score Matching: Meta-Analysis and Systematic Reviews
1被引7阅读
